- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05068141
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
October 13, 2021 updated by: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Single-arm, Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
This is a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of SG001 in combination with Nab-paclitaxel in patients with advanced TNBC.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a single-arm, open label, multicenter phase II study to evaluate the efficacy and safety of SG001 in combination with nab-paclitaxel in patients with unresectable locally advanced, or recurrent, or metastatic TNBC.
Eligible patients will receive SG001 intravenous infusion at a dose of 240 mg on Days 1 and 15 of every 4-week cycle and nab-paclitaxel intravenous infusion at a dose of 100 mg/m^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or intolerable toxicity, or other discontinuation or termination criteria are met, for a maximum of 2 years.
Study Type
Interventional
Enrollment (Anticipated)
79
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: beibei Zhai
- Phone Number: +86-021-60673937
- Email: zhaibeibei@mail.ecspc.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contact:
- herui yao, M.D
- Phone Number: +86-020-81332199
- Email: yaoherui@163.com
-
Contact:
- ying wang, M.D
- Phone Number: +86-020-81332199
- Email: yingwang1101@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female patients, aged 18-70 years (inclusive), voluntarily join the study and sign the informed consent form.
- Eastern Cooperative Oncology Group (ECOG) (ECOG): 0 ~ 1 point;
- Histologically confirmed TNBC, namely, human epidermal growth receptor 2-negative (HER2-negative) and estrogen receptor-negative (ER-negative) and progesterone receptor-negative (PR-negative); Patients with confirmed TNBC metastatic lesions are eligible.
- Patients with locally advanced (staging according to AJCC 8th Edition) inoperable or recurrent/metastatic TNBC who have received ≤ 1-line system treatment. The number of treatment-naïve patients and the pre-treated patients should be approximately in equal numbers. The interval ≥ 6 months between the end of taxane-based adjuvant/neoadjuvant therapy and the occurrence of recurrence/metastasis, and an interval ≥ 3 months between the end of taxane-based therapy for advanced breast cancer and the occurrence of recurrence/metastasis.
Provide archived tissue for detecting the expression level of PD-L1, or if not available, agree to perform a tumor tissue biopsy for PD-L1 detection during the screening period.
- The proportion of patients with CPS ≥ 10 should be ≥ 20% and ≤ 50% of all patients;
- The archived tissue must be representative of the latest tumor specimen, and the relevant pathological reports of the above specimens must also be provided;
- Fresh tissue specimens can be obtained by surgical resection and biopsy; Fine needle aspiration and liquid based cytology (TCT) samples are not accepted (i.e. samples lacking complete tissue structure and providing only cell suspension and/or cell smear);
- For patients with negative PD-L1 in the initially archived tumor tissue samples, biopsy can be performed during screening period to redetect the expression status of PD-L1 with the consent of the patients, and a positive tumor tissue sample of any kind is considered PD-L1 positive (i.e. CPS ≥ 1);
- At least one measurable lesion confirmed by CT or MRI at baseline as per the solid tumor efficacy evaluation criteria (RECIST v1.1). The measurable lesions should not have received local treatment such as radiotherapy (lesions located in the previous radiotherapy area can also be selected as target lesions if progression is confirmed);
- Estimated survival time ≥ 12 weeks;
Adequate organ function, defined by the following laboratory results obtained within 14 days prior to the enrollment::
- Blood routine (no blood transfusion within 14 days before the first administration, no hematopoietic stimulating factor and no other drugs to correct the number of blood cells): neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count (PLT) ≥ 75 × 109/L; Hemoglobin (HGB) ≥ 9 g/dL;
- Blood biochemistry: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCR) ≥ 50 mL/min; Total bilirubin (TBIL) ≤ 1.5 × ULN (≤ 3 × ULN for patients with Gilbert's syndrome); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN for patients with hepatocellular carcinoma or liver metastasis);
- Coagulation function: activated partial thromboplastin time (APTT) and international standardized ratio (INR) ≤ 1.5 × ULN (not corrected with anticoagulants or other drugs affecting coagulation function within 14 days before the first dose, except for the long-term use of anticoagulants due to the patient's disease);
- Women of childbearing age must take adequate contraceptive measures from the signing of informed consent to 6 months after the last dose.
Exclusion Criteria:
- Known hypersensitivity to recombinant anti-PD-1 all human monoclonal antibody drugs and its components, or known allergy to any paclitaxel or albumin bound paclitaxel component; A history of uncontrollable allergic asthma;
- Previously diagnosed other malignancies within 3 years prior to screening, except for adequately treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, thyroid cancer or cured in situ carcinoma, such as cervical carcinoma in situ;
- Patients with active autoimmune disease or history of autoimmune disease, except for well-controlled type I diabetes, well-controlled hypothyroidism only requiring hormone replacement therapy, skin disease that do not require systemic treatment (such as vitiligo, psoriasis, or alopecia), or patients whose diseases are not expected to recur in the absence of external triggers;
- Patients with a history of primary immunodeficiency;
- Patients with serious cardiovascular diseases, such as heart failure rated as grade 2 or above by the New York Heart Association (NYHA) classification, myocardial infarction within 3 months before screening, poorly controlled arrhythmia or unstable angina pectoris, or serious arterial/venous thrombotic events (such as transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep vein thrombosis and pulmonary embolism, etc.) within 3 months prior to screening;
- Interstitial lung disease requiring systemic therapy of glucocorticoid;
- Known untreated central nervous system (CNS) metastasis and meningeal metastasis, or treated but still symptomatic CNS metastasis and meningeal metastasis; However, asymptomatic untreated CNS metastasis and meningeal metastasis, and treated and symptomatically stable CNS metastasis and meningeal metastasis can be included.
- Have received any other antibodies/drugs that act on T-cell co-stimulation or checkpoint pathway (including but not limited to PD-1, PD-L1, PD-L2, CTLA-4, OX40, c137 inhibitors, etc.);
- Major surgery within 28 days before the first dose of study treatment, radiotherapy within 14 days before the first dose of study treatment, or use of radiation agents (strontium, or samarium, etc.) within 56 days before the first administration;
- Systemic antitumor therapy within 14 days before the first administration;
- Patients who have received live attenuated vaccine within 28 days before the first administration or planned to receive it during the study period.
- Any Chinese patent medicine treatment with an approved antitumor indication by NMPA or Chinese herbal medicine treatment for the purpose of antitumor which is clearly recorded in the medical record within 14 days before the first administration;
- Active tuberculosis;
- Active infection requiring intravenous infusion treatment within 14 days before the first administration;
- Received glucocorticoid (prednisone > 10 mg/day or equivalent dose of other similar drugs) or other immunosuppressive treatment for some conditions within 14 days before the first administration;
- Those who have received other test drugs within 28 days before the first administration;
- Human immunodeficiency virus antibody (HIV-Ab) or treponema pallidum antibody (TP-AB) positive; Hepatitis B virus surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive, with hepatitis B virus quantitative detection value > upper limit of normal (ULN) value of the detected center; Hepatitis C antibody (HCV-Ab) positive, with hepatitis B virus RNA quantification > ULN value of the detected center.
- Pregnant or lactating women; Or positive test for blood pregnancy during screening;
- Other situations that may increase the risks related to the study medication, interfere with the interpretation of the study results, affect compliance of the trial, etc. are determined by the investigator to be not suitable for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SG001 plus Nab-Paclitaxel
Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.
|
Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
Paclitaxel for Injection (Albumin Bound), 100 mg/m^2, i.v., D1, D8, D15 of every 4-week cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to approximately 2 years
|
ORR will be assessed by RECIST 1.1 criteria.
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Progression-free survival (PFS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Duration of response (DOR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Progression free survival (PFS) in patients with combined positive score (CPS) ≥ 10
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Objective response rate (ORR) in patients with CPS ≥ 10
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Duration of response (DOR) in patients with CPS ≥ 10
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Disease control rate (DCR) in patients with CPS ≥ 10
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Overall survival (OS) in patients with CPS ≥ 10
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Treatment emergent adverse event (TEAEs)
Time Frame: Throughout the study period, with an average of 2 years
|
Throughout the study period, with an average of 2 years
|
|
Maximum Serum Concentration (Cmax) for SG001 Maximum Serum Concentration for SG001 Maximum Serum Concentration (Cmax) for SG001
Time Frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Maximum Serum Concentration for SG001
|
Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Minimum Serum Concentration (Cmin) for SG001
Time Frame: Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Minimum Serum Concentration for SG001
|
Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Plasma Concentrations of Total and Free Paclitaxel
Time Frame: Pre-dose on Cycle 1 Day 1. End of nab-paclitaxel infusion, 4 hours after end of nab-paclitaxel infusion on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Plasma Concentrations of Total and Free Paclitaxel
|
Pre-dose on Cycle 1 Day 1. End of nab-paclitaxel infusion, 4 hours after end of nab-paclitaxel infusion on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days)
|
Immunogenicity
Time Frame: Up to approximately 2 years
|
Anti-drug antibodies (ADA) and neutralizing antibodies
|
Up to approximately 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between clinical characteristics and efficacy
Time Frame: Up to approximately 2 years
|
Clinical characteristics includes intestinal flora, gene mutations, PD-L1 expression, biomarkers, etc.
|
Up to approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: herui yao, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
- Study Chair: wang ying, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2021
Primary Completion (Anticipated)
October 1, 2022
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
September 9, 2021
First Submitted That Met QC Criteria
September 23, 2021
First Posted (Actual)
October 5, 2021
Study Record Updates
Last Update Posted (Actual)
October 15, 2021
Last Update Submitted That Met QC Criteria
October 13, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYSA1802-CSP-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on SG001
-
Shanghai Runshi Pharmaceutical Technology Co., LtdNot yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingAdvanced Solid Tumors
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Shanghai JMT-Bio Inc.Not yet recruitingMetastatic Colorectal Cancer (mCRC)
-
Bristol-Myers SquibbCompletedProstate CancerUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced Unresectable Esophageal Squamous CarcinomaChina
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingIntrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Advanced Biliary Tract Cancer | Extrahepatic CholangiocarcinomaChina